Study of oxidative stress in advanced kidney disease;Estudio del estrés oxidativo en enfermedad renal avanzada

Nefrologia

Volumn 29, Issue 5, 2009, Pages 464-473

  Montesa, M J Puchades ^a   Rico, M A González ^a   Salguero, M A Solís ^a   Maicas, I Torregrosa ^a   Muñoz, M C Tormos ^b   Tormo, G Sáez ^c   García, I Juan ^a   Carrasco, A Miguel ^a  

^a HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

^b UNIVERSITY OF VALENCIA   (Spain)

^c Valencia General University Hospital   (Spain)

Author keywords

8 oxo deoxiguanosin; Chronic kidney disease; Oxidative stress

Indexed keywords

AGED; ARTICLE; CHRONIC DISEASE; DISEASE COURSE; FEMALE; HUMAN; KIDNEY DISEASE; MALE; METABOLISM; MIDDLE AGED; OXIDATIVE STRESS;

AGED; CHRONIC DISEASE; DISEASE PROGRESSION; FEMALE; HUMANS; KIDNEY DISEASES; MALE; MIDDLE AGED; OXIDATIVE STRESS;

EID: 72749125013     PISSN: 02116995     EISSN: None     Source Type: Journal    
DOI: 10.3265/NEFROLOGIA.2009.29.5.5493.EN.FULL     Document Type: Article

References (35)

1. De Francisco AL. Revisiones SEN. Academia de Nefrología. La necesidad de enfrentarnos a la ERC como enfermedad epidémica. En: Euromedice Ediciones Médicas SL, 2006.
2. Coresh J, Astot BC, Greene T, Eknoyan G, Levey AS. Prevalence of chronic kidney disease and decrese kidney function in the adult US population: Third National Health and Nutrition Examination Survey. Am J Kidney Dis 2003;41(41):1-12.
3. Registros de Enfermos Renales. Informe de diálisis y trasplante 2006. Grupo de Registros de Enfermos Renales. www.senefro.org.
4. Foley RN, Parfey PS, Sarnak MJ. Clinical epidemiology of cardiovascular disease in Chronic Kidney Disease. Am J Kid Dis 1998;32(S3):112-9.
5. Arici M, Walls J. End-stage renal disease, atherosclerosis, and cardiovascular mortality: Is C reactive protein the missing link? Kidney Int 2001;59:407-14.
6. Pumpin LB, Himmelfarb J, McMonagle E, Shyr Y, Ikizler TA. Influence of initiation of maintenance hemodialisis on biomarkers of inflammation and oxidative stress. Kidney Int 2004;65:2371-9.
7. Himmelfarb J, Stenvinkel P, Ikizler TA, et al. The elephant in uremia: Oxidant stress as a unifying concept of cardiovascular disease in uremia. Kidney Int 2002;62:1524-38.
8. Payson Oberg B, McMenamin E, Lee Lucas F, et al.Increased prevalence of oxidant stress and inflammation in patients with moderate to severe chronic kidney disease. Kidney Int 65 2004;1009-16.
9. Boyum A. Isolation of mononuclear cells and granulocytes from human blood. Scan J Clin Lab Invest 1968;21:77-89.
10. Muñiz P, Valls V, Pérez-Broseta C, Iradi A, Climent JV, Oliva MR, et al. The role of 8-hydroxy-2'-deoxyguanosine in ryfamycin-induced DNA damage. Free Radic Biol Med 1995;18:747-55.
11. Espinosa O, Jiménez-Almazan J, Chaves FJ, Tormos MC, et al. Urinary 8-oxo-7,8-dihydro-2'-deoxyguanosine (8-oxo-dG), a reliable oxidative stress marker in hypertension. Free Radic Res 2007;41:546-54.
12. Higuchi M Yoshida. Lowry determination of protein in the presence of sulfhydryl compounds or other reducting agents. Annals Biochem 1977;77:542-7.
13. Buss H, Chan TP, Sluis KB, Domigan NM, Winterbourn CC. Protein Carbonyl measurement by a sensitive ELISA method. Free Radic Biol Med 1997;23:361-6.
14. Mc Cord JM, Fridowich I. The reduction of citochrome C by milk xanthine oxidase. J Biol Chem 1968;243:5753-60.
15. Clairbone A. Catalase activity. En: Green-Wald RA, ed. Handbook of methods for Oxygen Radical Research. Boca Raton, FL: CRC Press Inc 1986:283-4.
16. Esterbauer H, Schaur RJ, Zollner H. Chemistry and biochemistry of 4-hidroxynonenal, malondialdehyde and related aldehydes. Free Radic Biol Med 1991;11:81-128.
17. Boaz M, Matas Z, Biro A, et al. Serum malondialdehyde and prevalent cardiovascular disease in hemodialysis. Kideny Int 1999;56:1078-83.
18. De Vecchi A F, Bamonti F, Novembrino C, et al. Free and total plasma malondialdehyde in chronic renal insufficiency and in dialysis patients. Nephrol Dial Transplant. Advance Access published on March 4, 2009; doi: 10,1093.
19. Handelman G, Walter MF, Adhikarla R, et al. Elevated plasma F2 isoprostanes in patients on long-term hemodialisis. Kidney Int 2001;59:1960-6.
20. Morrow JD, Frei B, Longmire AW, et al. Increased in circulating products of lipid peroxidation (F2 isoprostanes) in smokers. Smoking as a cause of oxidative damage. N Eng J Med 1995;332:1198-203.
21. Gopaul NK, Anggard EE, Mallet AI, et al. Plasma 8-epi-PGF2 alpha leveles are elevated in individuals with non-insulin dependent diabetes mellitus. FEBS Lett 1995;368:225-9.
22. Cottone S, Mulè G, Guarneri M, et al. Endothelin-1 and F2 isoprostane relate to and predict renal dysfunction in hypertensive patients. Nephrol Dial Trasplant 2009;24:497-503.
23. Donousi E, Papavasiliou E, Makedou A, Ioannou K. Oxidative Stress is progressively enhanced with advancing stages of CKD. Am J Kidney Dis 2006;48(5):752-60.
24. Oberg BP, Mc Menamin E, Lucas F, McMonagle E. Increased prevalence of oxidant stress and inflammation in patients with moderate to severe chronic kidney disease. Kidney Int 2004;65:1009-16.
25. Satoh M, Yamasaki Y, Nagake Y, et al. Oxidative stress is reduced by the long term use of vitamin E coated dialysis filters. Kidey Int 2001;59:1943-50.
26. Tarng D, Huang T, Liu T, et al. Effect of vitamin E-bonded membrane on the 8-hydroxy 2' deoxyguanosine level in leukocite DNA of hemodialysis damage. Kidney Int 2000;58:790-9.
27. Lodovi M, Casalini C, Carriaggi R, et al. Levels of 8-hydroxydeoxiguanosine as a marker of DNA damage in human leukocites. Free Radic Biol Med 2000;28:13-7.
28. Arizawa T, Kinugasa E, Koshikawa S. Increased risk of malignancy and blood-membrane interactions in uremic patients. Nephrol Dial Transplant 1994;9(2):162-4.
29. Redón J, Oliva MR, Tormos C, Giner V, et al. Antioxidant activities and Oxidative stress byproducts in Human Hypertension. Hypertension 2003;41:1096-101.
30. Heinecke JW. Mass spectrometric quantification of amino acid oxidation products in protein: Insights into pathways that promote LDL oxidation in the human artery wall. FASEB J 1999;13:113-1120.
31. Heinecke JW. Mechanisms of oxidative damage by mieloperoxidase in atherosclerosis and other inflammatory disease. J Lab Clin Med 1999;133:321-5.
32. Daugherty A, Dunn JL, Rateri DL, Heninecke JW. Mieloperoxidase, a catalyst for lipoprotein oxidation, is expressed in human atherosclerotic lesions. J Clin Invest 1994;94:437-44.
33. Zhang R, Brennan ML, Fu X, Avilés RJ, Pearce GL, Penn MS, et al. Association between myeloperoxidase levels and risk of coronary artery disease. JAMA 2001;286:2136-42.
34. Witko-Sarsat V, Friedlander M, Nguyen Khoa T, et al. Advanced Oxidation Protein Products as novel mediators of inflammation and Monocyte Activation in Chronic Renal Failure. J Inmunol 1998;161:2524-32.
35. Moradi H, Pahl MV, Elahimer R, Vaziri ND. Impaired antioxidant activity of high density lipoprotein in chronic kidney disease. Transl Res 2009;153(2):77-85.